Treceți offline cu aplicația Player FM !
Podcasturi care merită ascultate
SPONSORIZAT
![Exile podcast artwork](https://cdn.player.fm/images/41381904/series/JWqznqfJ6qlGsgub/32.jpg 32w, https://cdn.player.fm/images/41381904/series/JWqznqfJ6qlGsgub/64.jpg 64w, https://cdn.player.fm/images/41381904/series/JWqznqfJ6qlGsgub/128.jpg 128w, https://cdn.player.fm/images/41381904/series/JWqznqfJ6qlGsgub/256.jpg 256w, https://cdn.player.fm/images/41381904/series/JWqznqfJ6qlGsgub/512.jpg 512w)
![Exile podcast artwork](/static/images/64pixel.png)
1 Episode 15: The Model Ghetto 41:22
Mark Lythgoe on UK oncology drug approval after Brexit
Manage episode 359135115 series 2829082
Dr Mark Lythgoe (Imperial College London, London, UK), discusses his new Review, "From The European Medicines Agency to Project Orbis: New activities and challenges to facilitate UK Oncology Drug Approval following Brexit".
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
206 episoade
Manage episode 359135115 series 2829082
Dr Mark Lythgoe (Imperial College London, London, UK), discusses his new Review, "From The European Medicines Agency to Project Orbis: New activities and challenges to facilitate UK Oncology Drug Approval following Brexit".
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
206 episoade
Alla avsnitt
×![Artwork](/static/images/128pixel.png)
1 Ian Tannock on Common Sense Oncology principles for phase 3 randomised clinical trials 18:03
![Artwork](/static/images/128pixel.png)
1 Yannick Romero on the changing landscape of national cancer control plans 24:40
![Artwork](/static/images/128pixel.png)
1 M Saiful Huq and Mostafa Aziz Sumon on the series Cancer Care in South Asian Association for Regional Cooperation (SAARC) Countries 22:15
![Artwork](/static/images/128pixel.png)
1 Steven Horwitz on valemetostat for relapsed or refractory T-cell lymphoma 15:07
![Artwork](/static/images/128pixel.png)
1 Zachary Zumsteg on early phase trial design for novel drug-radiotherapy combination 17:21
![Artwork](/static/images/128pixel.png)
1 May Abdel-Wahab and Andrew Scott on The Lancet Oncology Commission on Radiotherapy and Theranostics 40:45
![Artwork](/static/images/128pixel.png)
1 Kanwal Raghav on trastuzumab deruxtecan in HER2-positive advanced colorectal cancer (DESTINY-CRC02) 13:22
![Artwork](/static/images/128pixel.png)
1 Emmy Boerrigter on dose selection of novel anticancer drugs 11:41
![Artwork](/static/images/128pixel.png)
1 Hisham Mehanna and Sue Yom on head and neck cancer consensus recommendations 36:56
![Artwork](/static/images/128pixel.png)
1 Garth Strohbehn and Katie Lichter on the environmental impact of cancer treatment 24:08
![Artwork](/static/images/128pixel.png)
1 James Shultz, Ana Patricia Ortiz, and Leticia Nogueira on cancer and compounding disasters in the Caribbean 35:05
![Artwork](/static/images/128pixel.png)
1 Bernardo Goulart on correlations of endpoints in lung cancer immunotherapy trials 11:22
![Artwork](/static/images/128pixel.png)
1 Maria Kyrgiou on innovations in gynaecological cancers and global disparities 25:42
![Artwork](/static/images/128pixel.png)
1 Georgios Lyratzopoulos on the use of chemotherapy and radiotherapy in patients with eight common cancers 34:43
![Artwork](/static/images/128pixel.png)
1 Mike Sathekge on radioligand therapy of metastatic castration-resistant prostate cancer 16:06
Bun venit la Player FM!
Player FM scanează web-ul pentru podcast-uri de înaltă calitate pentru a vă putea bucura acum. Este cea mai bună aplicație pentru podcast și funcționează pe Android, iPhone și pe web. Înscrieți-vă pentru a sincroniza abonamentele pe toate dispozitivele.